Advances of pathological complete response after neoadjuvant therapy for pancreatic cancer
Abstract. Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy with a poor prognosis. Only 15% to 20% of patients present with a primarily resectable tumor at the time of diagnosis. There has been an increasing interest in the use of neoadjuvant chemotherapy alone or combination with...
| Published in: | Journal of Pancreatology |
|---|---|
| Main Authors: | , , |
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Health/LWW
2019-03-01
|
| Online Access: | http://journals.lww.com/10.1097/JP9.0000000000000009 |